Importance Clinical trial activity in amyotrophic lateral sclerosis (ALS) is dramatically
increasing; as a result, trial modifications have been introduced to improve efficiency …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
loss of upper and lower motor neurons, resulting in progressive weakness of all voluntary …

RFC1 disease, caused by biallelic repeat expansion in RFC1, is clinically heterogeneous in
terms of age of onset, disease progression and phenotype. We investigated the role of the …

Erythrocytes play a fundamental role in oxygen delivery to tissues and binding to
inflammatory mediators. Evidences suggest that dysregulated erythrocyte function could …

We analysed clinical trials of pharmacological interventions on patients with amyotrophic
lateral sclerosis (ALS), and compared study quality and design features. The systematic …

Vitamins and essential metals have been studied as potential risk and prognostic factors in
amyotrophic lateral sclerosis (ALS). This study aimed to evaluate the prevalence of …

Objective Neuronata-R®(lenzumestrocel) is an autologous bone marrow-derived
mesenchymal stem cell (BM-MSC) product, which was conditionally approved by the Korean …

Background and purpose Progression rate is quite variable in amyotrophic lateral sclerosis
(ALS); thus, tools for profiling disease progression are essential for timely interventions. The …

Abstract Introduction/Aims Rate of disease progression (ΔFS), measured as change in the
revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS‐R) and body mass …

Although reductions in lingual strength are reported in individuals with amyotrophic lateral
sclerosis (ALS) that are associated with dysphagia; determination of a functional lingual …